- Delta-9-THC (active): detectable 3-12 hours after inhalation for infrequent users; up to 25 days (serum THC-COOH) for heavy chronic users
- Blood tests are used for DUID (driving under the influence of drugs) enforcement — they assess recent use, not long-term history
- Colorado and Washington: 5 ng/mL delta-9-THC per se limit; Pennsylvania: 1 ng/mL; most states: impairment standard only
- Oral fluid (saliva) testing is increasingly used for roadside screening — detects parent THC for 4-24 hours
- Chronic users may exceed per se limits for hours to days after last use without any current impairment — tolerance effect
- Passive exposure cannot cause a positive blood test — concentrations remain far below per se limits
- GC-MS and LC-MS/MS are the laboratory gold standards for blood THC analysis
Blood Test vs. Urine Test: Different Purposes, Different Compounds
Cannabis blood testing and urine testing serve fundamentally different purposes and detect different compounds with different time windows. Understanding this distinction is essential for interpreting what a blood test can and cannot tell you.
Urine tests detect THC-COOH glucuronide — the conjugated, inactive metabolite excreted by the kidneys. Urine testing is used for workplace drug screening, probation compliance, and pre-employment testing. It answers the question: did this person use cannabis in the past several days (or weeks for heavy users)? It says nothing about current impairment.
Blood tests detect delta-9-THC (the psychoactive parent compound), 11-OH-THC (active metabolite), and THC-COOH (inactive metabolite) in whole blood or serum. Blood testing is used primarily in DUID (driving under the influence of drugs) investigations, where the goal is to establish recent consumption and potential impairment. Blood tests answer a closer question to "did this person use cannabis recently?" — but even here, the correlation with impairment is imperfect.
THC Blood Detection Windows by Use Frequency
| Use Pattern | Delta-9-THC (active) Detection | 11-OH-THC Detection | THC-COOH (serum) Detection | Notes |
|---|---|---|---|---|
| Single inhalation | 3-6 hours | 2-4 hours | 12-24 hours | Rapid decline after peak at ~10 min |
| Single edible dose | 6-25 hours | 8-20 hours | 24-48 hours | Slower onset, higher 11-OH-THC ratio |
| Occasional (1-3×/week) | 12-24 hours | 6-12 hours | 2-5 days | Limited adipose accumulation |
| Regular (daily) | 24-48 hours | 12-24 hours | 5-14 days | Adipose reservoir extends window |
| Heavy chronic (multiple/day) | 24-72 hours | 24-48 hours | Up to 25 days (serum COOH) | Tolerance effect: high blood THC without behavioral impairment |
The key complication for enforcement is the last row. A heavy chronic cannabis user may have blood THC concentrations that exceed per se limits (5 ng/mL in CO/WA) for 24-72 hours after their last use — long after any psychoactive impairment has resolved due to tolerance. Chronic exposure causes CB1 receptor downregulation and desensitization, meaning the same blood THC concentration produces far less functional impairment in a chronic user than in an occasional user.
Per Se Limits vs. Impairment Standards: State-by-State
There is no federal cannabis impairment standard for driving equivalent to the 0.08% BAC alcohol standard. States have adopted widely varying approaches.
| State | Legal Standard | THC Limit | Specimen Type | Notes |
|---|---|---|---|---|
| Colorado | Per se + inference | 5 ng/mL delta-9-THC | Whole blood | 5 ng/mL creates permissive inference of impairment, not automatic guilt |
| Washington | Per se | 5 ng/mL delta-9-THC | Whole blood | Strict per se; 5 ng/mL = DUI per RCW 46.61.502 |
| Pennsylvania | Per se (zero-ish) | 1 ng/mL delta-9-THC | Whole blood | Among strictest in US |
| California | Impairment only | No per se limit | Blood (post-arrest) | VC § 23152(f) — prosecutor must prove impairment via evidence |
| New York | Impairment only | No per se limit | Blood (post-arrest) | Requires impairment evidence beyond blood test |
| Florida | Per se | 5 ng/mL delta-9-THC | Blood or urine | FL Statute 316.193 |
| Illinois | Per se | 5 ng/mL delta-9-THC (blood) / 10 ng/mL (oral fluid) | Blood or oral fluid | 625 ILCS 5/11-501.2 |
| Utah | Zero tolerance | Any detectable THC metabolite | Blood or urine | UC § 41-6a-517 — any metabolite = DUI |
| Arkansas | Per se + zero tolerance for metabolites | Any metabolite | Blood or urine | ACA § 5-65-103 |
| Most other states | Impairment standard | No numeric limit | Blood (post-arrest) | Blood THC is one piece of evidence, not determinative |
DUID Enforcement: What Happens at a Traffic Stop
When a law enforcement officer suspects cannabis impairment during a traffic stop, the sequence typically proceeds as follows:
Field sobriety tests: Standardized field sobriety tests (HGN, walk-and-turn, one-leg stand) are validated for alcohol impairment. They are less reliable indicators of cannabis impairment, but officers use them as initial screening. Cannabis intoxication may produce some indicators (modified Romberg balance, pupil size changes) that alcohol does not.
Drug Recognition Expert (DRE): In serious cases, a specially trained DRE officer may conduct a 12-step evaluation protocol that includes pulse rate, pupil size, divided attention tests, and vital signs. DRE protocols are designed to identify drug category impairment without requiring blood test results.
Blood draw (post-arrest): Following arrest, a blood draw is requested (or compelled under implied consent laws). The blood specimen is sent to a state laboratory for GC-MS or LC-MS/MS analysis. Results typically take days to weeks to return, meaning the arrest decision was made without the blood test data.
Oral fluid roadside screening: Several states now use oral fluid screening devices (Dräger DrugTest 5000, SoToxa) at the roadside to provide rapid probable cause for DRE evaluation or arrest. These devices detect parent THC in saliva with approximate 4-24 hour windows.
Blood vs. Oral Fluid for Roadside Testing
Oral fluid testing has significant practical advantages over blood for roadside cannabis enforcement: it is non-invasive, does not require a trained phlebotomist, provides rapid results (10-15 minutes), and detects parent THC with a window that better correlates with recent use than blood metabolite testing.
The DropSafe oral fluid collection device and SoToxa Mobile Test System (Abbott Diagnostics) represent two platforms increasingly deployed by law enforcement. Illinois mandates oral fluid testing as an option under 625 ILCS 5/11-501.2. Michigan, Minnesota, and several Canadian provinces have active oral fluid pilot programs or mandates.
The scientific challenge is that oral fluid THC concentrations decline rapidly and are influenced by the route of administration, time since last use, and salivary pH and composition — making a precise "per se" oral fluid limit scientifically complex. Illinois uses 10 ng/mL delta-9-THC in oral fluid as its threshold, calibrated to approximate recency of use rather than impairment per se.
Medical Cannabis Patients and Blood Tests
Medical cannabis patients on therapeutic doses present a particular challenge for blood testing enforcement. Regular therapeutic use builds tolerance, meaning a patient may maintain blood THC concentrations above per se limits for extended periods while experiencing no functional impairment whatsoever. This is analogous to a chronic opioid patient who can drive safely at plasma morphine concentrations that would incapacitate a naive user.
Courts in impairment-standard states (CA, NY, most of the country) have room to present expert testimony about tolerance and impairment standards. In per se states (CO, WA, PA, FL), patients have more limited legal recourse if blood THC exceeds the statutory limit at the time of blood draw — even without behavioral evidence of impairment.
Medical cannabis patients in Colorado who have been prosecuted under the 5 ng/mL standard have argued constitutional challenges, with mixed results. The Colorado Supreme Court in 2021 (People v. Carbajal) ruled that the permissive inference structure of the law (not an automatic per se standard) provides sufficient constitutional protection.
Lab Methodology: How Blood THC Is Measured
Blood THC analysis in forensic contexts uses a two-step process similar to urine testing: immunoassay screening followed by mass spectrometry confirmation.
Immunoassay screening (ELISA): Enzyme-linked immunosorbent assay provides a rapid positive/negative indication. Cross-reactivity is less of a concern with blood than urine because fewer interfering substances reach blood at relevant concentrations.
GC-MS (Gas Chromatography-Mass Spectrometry): The traditional forensic gold standard. Blood is extracted (protein precipitation + liquid-liquid extraction), derivatized for gas-phase analysis, and separated by the column before mass spectrometric identification. Quantification limits typically 0.5-1 ng/mL for delta-9-THC.
LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry): Increasingly preferred over GC-MS for cannabis blood analysis because it does not require derivatization, handles the polarity of THC-COOH glucuronide more efficiently, and achieves lower detection limits (0.1-0.5 ng/mL). Particularly useful for identifying the full metabolite profile simultaneously.
Frequently Asked Questions
How long does THC show up in a blood test?
For infrequent users: delta-9-THC detectable 3-12 hours after inhalation. For heavy chronic users: up to 25 days for THC-COOH in serum. Parent THC (the active compound) typically clears within 24-72 hours even in heavy users. Blood tests are used for DUID investigation, not long-term history screening.
What is the legal blood THC limit for driving?
Colorado and Washington: 5 ng/mL delta-9-THC (per se). Pennsylvania: 1 ng/mL. Florida, Illinois: 5 ng/mL. California, New York, and most states: impairment standard only — blood THC is evidence, not automatic guilt. Utah and Arkansas use zero tolerance for any detectable metabolite.
Can passive cannabis smoke exposure cause a positive blood test?
No. Passive exposure produces blood THC far below any per se limit or impairment level. Only direct inhalation or oral consumption generates relevant blood THC concentrations.
Why do blood tests show cannabis days after use without current impairment?
THC-COOH (the inactive metabolite) persists in blood serum for days to weeks in chronic users. A positive serum THC-COOH result days after last use does not indicate current impairment. Parent delta-9-THC is a better impairment marker but still imperfect — chronic users develop tolerance and can have elevated blood THC without functional impairment.